The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AURKA blockage as a strategy to overcome resistance to olaparib and platinum in high-grade ovarian cancer (HGOC).
 
Juan José Martínez-Pretel
No Relationships to Disclose
 
Victoria Heredia
No Relationships to Disclose
 
Miriam Ruiz Linuesa
No Relationships to Disclose
 
Paloma Sanchez Serrano
No Relationships to Disclose
 
Lidia Gonzalez Villena
No Relationships to Disclose
 
Marta Mendiola
Honoraria - AstraZeneca; GlaxoSmithKline; MSD Oncology
Research Funding - Eisai (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer; PharmaMar; Roche
 
Andres Redondo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD
Travel, Accommodations, Expenses - AstraZeneca
 
Begoña Pineda
No Relationships to Disclose
 
Jose Alejandro Perez-Fidalgo
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline
Speakers' Bureau - AstraZeneca Spain; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology; PharmaMar; Seagen
Research Funding - AstraZeneca Spain (Inst); GlaxoSmithKline (Inst); Pharmamar (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca Spain; Novartis